PCSK9 INHIBITORS IN CONTROLLING LIPID PROFILE AND LIPOPROTEIN(A) IN END-STAGE KIDNEY DISEASE: A CASE REPORT

Thị Ngọc Bích Phạm1, , Tỏa Ngọc Trâm Dương1, Trung Kiên Trần1
1 Bệnh viện đa khoa Tâm Anh

Main Article Content

Abstract

Background: Dyslipidemia in end-stage kidney disease (ESKD) patients undergoing hemodialysis is highly atherogenic and complex. Real-world evidence regarding the safety and efficacy of PCSK9 monoclonal antibody inhibitors in this population remains scarce in Vietnam.


Case report: A 56-year-old man with hypertension, type 2 diabetes, and ESKD had been counseled regarding renal replacement therapy but had not started maintenance hemodialysis before admission and was undergoing evaluation for kidney transplantation. He was admitted with acute pulmonary edema/acute decompensated heart failure (LVEF 38%), underwent emergency hemodialysis, and was subsequently transitioned to thrice-weekly maintenance hemodialysis. Coronary computed tomography angiography revealed an Agatston score of 404 and severe multivessel coronary artery disease, for which percutaneous coronary intervention with four drug-eluting stents was performed. The patient was classified as being at very high cardiovascular risk, with a baseline LDL-C level of 3.45 mmol/L (133.4 mg/dL) and an Lp(a) level of 64.6 mg/dL. Despite treatment with atorvastatin 40 mg plus ezetimibe 10 mg/day, his LDL-C remained above the recommended target (1.96 mmol/L). Evolocumab 140 mg was added subcutaneously every 2 weeks to the oral lipid-lowering regimen. Its large molecular size prevents clearance through the dialysis membrane, allowing administration independently of the hemodialysis schedule. After 1 month of triple therapy, LDL-C decreased to 0.61 mmol/L (an 82.3% reduction from baseline, achieving the target of <1.4 mmol/L), while Lp(a) decreased to 57.26 mg/dL (an 11.4% reduction). The regimen was well tolerated, with no adverse events reported.


Conclusion: The combination of a statin, ezetimibe, and evolocumab achieved a profound reduction in LDL-C, supported Lp(a) control, and appeared safe and convenient in an ESKD patient receiving maintenance hemodialysis after percutaneous coronary intervention.

Article Details

References

1. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192.
2. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014;160(3):182-189.
3. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722.
4. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Guo J, et al. Efficacy and safety of evolocumab in individuals with cardiovascular disease and chronic kidney disease: a prespecified secondary analysis of the FOURIER randomized clinical trial. Lancet Diabetes Endocrinol. 2019;7(11):853-861.
5. O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and risk of cardiovascular events in the FOURIER trial. Circulation. 2019;139(12):1483-1492.
6. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.
7. Toth PP, Jones LK, Ambegaonkar BM, Fan W, Philip S, Philip P, et al. Safety and efficacy of evolocumab in patients with severe renal impairment or end-stage renal disease on hemodialysis. J Am Coll Cardiol. 2020;75(11_Suppl_1):1858.
8. Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Clin Exp Nephrol. 2012;16(2):238-243.